136 related articles for article (PubMed ID: 7625815)
1. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; Trujillano I; García Sánchez E; García García MI; Fresnadillo MJ
Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
[TBL] [Abstract][Full Text] [Related]
2. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey.
Yamazhan T; Aydemir S; Tünger A; Serter D; Gökengin D
Med Princ Pract; 2005; 14(6):413-6. PubMed ID: 16220015
[TBL] [Abstract][Full Text] [Related]
4. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis.
García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo MJ
J Chemother; 1994 Apr; 6(2):102-6. PubMed ID: 8077983
[TBL] [Abstract][Full Text] [Related]
5. [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].
Alişkan H; Turunç T; Demiroğlu YZ; Colakoğlu S; Arslan H
Mikrobiyol Bul; 2008 Jan; 42(1):125-9. PubMed ID: 18444570
[TBL] [Abstract][Full Text] [Related]
6. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs.
Qadri SM; Ueno Y
Chemotherapy; 1993; 39(2):128-31. PubMed ID: 8384544
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
Qadri SM; Ayub A; Ueno Y; Saldin H
Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of six new fluoroquinolones against Brucella melitensis.
Trujillano-Martín I; García-Sánchez E; Martínez IM; Fresnadillo MJ; García-Sánchez JE; García-Rodríguez JA
Antimicrob Agents Chemother; 1999 Jan; 43(1):194-5. PubMed ID: 9869594
[TBL] [Abstract][Full Text] [Related]
10. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
Ford AS; Baltch AL; Smith RP; Ritz W
J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
[TBL] [Abstract][Full Text] [Related]
11. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
Qadri SM; Ueno Y; Ayub A
Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
[TBL] [Abstract][Full Text] [Related]
12. Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
Borobio MV; Conejo M; Ramirez E; Suarez AI; Perea EJ
Antimicrob Agents Chemother; 1994 Jun; 38(6):1442-5. PubMed ID: 8092852
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey.
Kocagöz S; Akova M; Altun B; Gür D; Hasçelik G
Clin Microbiol Infect; 2002 Apr; 8(4):240-2. PubMed ID: 12047416
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
Deshpande LM; Diekema DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):81-8. PubMed ID: 10529885
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
[TBL] [Abstract][Full Text] [Related]
17. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.
Kilic S; Dizbay M; Cabadak H
J Chemother; 2008 Feb; 20(1):33-7. PubMed ID: 18390405
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of CS-940, a new trifluorinated quinolone.
Biedenbach DJ; Sutton LD; Jones RN
Antimicrob Agents Chemother; 1995 Oct; 39(10):2325-30. PubMed ID: 8619590
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.
Khan MY; Dizon M; Kiel FW
Antimicrob Agents Chemother; 1989 Aug; 33(8):1409-10. PubMed ID: 2802568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
